Skip to Main Content
Skip Nav Destination

A novel analytical approach for quantifying Daridorexant (DXT) in plasma has been devised using suvorexant as an internal standard (IS), To separate the DXT from the plasma, liquid-liquid extraction (LLE) was utilized, followed by RP-HPLC analysis using a PDA. DXT recovery was tested with several extraction solvents (n-butyl chloride, ether / toluene (1: 1), and methyl t-butyl ether (MTBE)). Analytes were separated on an Inertsil ODS column (250 x 4.6 mm, 5µ) using a 0.5 mM sodium acetate buffer (pH-3.5): methanol (78:22 v/v) as mobile phase pumped at 0.5 mL/min. The temperature in the column was kept constant at 25 °C and drug was monitored at 225 nm. The proposed technique was validated in accordance with the USFDA guidelines. Linearity was established in a range of 0.25 to 10.00 µg/mL. The LOQ was determined to be 0.13 µg/mL. The mean accuracy (% CV) was found to be less than 15% of ranging from 92 to 115% of the nominal concentration. In HQC 8.50 µg/mL and LOQ 0.750 µg/mL, the matrix impact was 2.24 and 4.51%, respectively. Plasma Quality Control (QC) samples were kept at -20° C. After three freeze-thaw cycles, first intraday quality control analysis revealed an accuracy of 4% of nominal with an accuracy (% CV) of 3.8%. QC plasma samples have been demonstrated to stay stable at -20 °C for up to 10 months. The method can be used to support clinical studies and/or bioavailability and bioequivalence studies.

This content is only available via PDF.
You do not currently have access to this chapter, but see below options to check access via your institution or sign in to purchase.
Don't already have an account? Register
Close Modal

or Create an Account

Close Modal
Close Modal